Results for:(26 found)
Jul 22, 2014 2:35PM on Top StocksBy MSN Money Partner

The category is seeing less enthusiasm from investors than any other.

Jan 28, 2014 4:24PM on Top StocksBy StreetAuthority

With the Affordable Care Act bringing millions more patients into the system, Lab Corp should have all the business it can handle for years to come.

Jan 15, 2014 12:58PM on Top StocksBy Forbes Digital

Illumina's new supercomputer can sequence the genetic code of a human cell at a relatively low cost. It's a milestone of huge psychological importance for science.

Sep 10, 2013 11:10AM on Top StocksBy MSN Money Partner

D.R. Horton is downgraded to 'neutral,' and Five Below is upgraded to 'neutral.'

Aug 15, 2013 10:58AM on Top StocksBy MSN Money Partner

Cisco is upgraded to 'neutral,' and Intel is downgraded to 'neutral.'

Jul 2, 2013 10:43AM on Top StocksBy MSN Money Partner

Gold stocks are downgraded at Jefferies, and Yelp is initiated with an 'outperform.'

Apr 23, 2013 1:46PM on Top StocksBy Forbes Digital

The two companies were working together on DNA sequencing technology, but the pharmaceutical giant pulled out Tuesday.

Apr 11, 2013 9:23AM on Top StocksBy Benzinga

Amgen, Celgene and Pharmacyclics see short interest drop recently.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More